Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of SK Japanese Encephalitis mRNA Vaccines (GBP560) in Healthy Adults
NCT06680128Phase 2Completed
- Sponsor
- SK bioscience
- Start
- Feb 2025
- Primary completion
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of GBP560 in Japanese encephalitis (JE), sponsored by SK bioscience. Started Feb 2025; status: completed.
02
Drugs
GBP560
03
Conditions
Japanese encephalitis (JE)
Beyond the preview
Go deeper on NCT06680128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06680128.